|
1
|
Louis DN, Ohgaki H, Wiestler OD, et al:
The 2007 WHO classification of tumours of the central nervous
system. Acta Neurophathol. 114:97–109. 2007. View Article : Google Scholar
|
|
2
|
Warburg O: On the origin of cancer cells.
Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jang M, Kim SS and Lee J: Cancer cell
metabolism: implications for therapeutic targets. Exp Mol Med.
45:e452013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dang L, Jin S and Su SM: IDH mutations in
glioma and acute myeloid leukemia. Trends Mol Med. 16:387–397.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fu Y, Huang R, Du J, Yang R, An N and
Liang A: Glioma-derived mutations in IDH: from mechanism to
potential therapy. Biochem Biophys Res Commun. 397:127–130. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Borodovsky A, Seltzer MJ and Riggins GJ:
Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2.
Curr Opin Oncol. 24:83–89. 2012. View Article : Google Scholar
|
|
7
|
Yan H, Parsons DW, Jin G, et al: IDH1 and
IDH2 mutations in gliomas. N Engl J Med. 360:765–773. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Turcan S, Rohle D, Goenka A, et al: IDH1
mutation is sufficient to establish the glioma hypermethylator
phenotype. Nature. 483:479–483. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kloosterhof NK, Bralten LB, Dubbink HJ,
French PJ and van den Bent MJ: Isocitrate dehydrogenase-1
mutations: a fundamentally new understanding of diffuse glioma?
Lancet Oncol. 12:83–91. 2011. View Article : Google Scholar
|
|
10
|
Gravendeel LA, Kloosterhof NK, Bralten LB,
et al: Segregation of non-p.R132H mutations in IDH1 in distinct
molecular subtypes of glioma. Hum Mutat. 31:E1186–E1199. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhao S, Lin Y, Xu W, et al: Glioma-derived
mutations in IDH1 dominantly inhibit IDH1 catalytic activity and
induce HIF-1alpha. Science. 324:261–265. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu W, Yang H, Liu Y, et al: Oncometabolite
2-hydroxyglutarate is a competitive inhibitor of
alpha-ketoglutarate-dependent dioxygenases. Cancer Cell. 19:17–30.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sanson M, Marie Y, Paris S, et al:
Isocitrate dehydrogenase 1 codon 132 mutation is an important
prognostic biomarker in gliomas. J Clin Oncol. 27:4150–4154. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Houillier C, Wang X, Kaloshi G, et al:
IDH1 or IDH2 mutations predict longer survival and response to
temozolomide in low-grade gliomas. Neurology. 75:1560–1566. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li S, Chou AP, Chen W, et al:
Overexpression of isocitrate dehydrogenase mutant proteins renders
glioma cells more sensitive to radiation. Neuro Oncol. 15:57–68.
2013. View Article : Google Scholar :
|
|
16
|
Elstrom RL, Bauer DE, Buzzai M, et al: Akt
stimulates aerobic glycolysis in cancer cells. Cancer Res.
64:3892–3899. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mobasheri A, Richardson S, Mobasheri R,
Shakibaei M and Hoyland JA: Hypoxia inducible factor-1 and
facilitative glucose transporters GLUT1 and GLUT3: putative
molecular components of the oxygen and glucose sensing apparatus in
articular chondrocytes. Histol Histopathol. 20:1327–1338.
2005.PubMed/NCBI
|
|
18
|
Wolf A, Agnihotri S, Micallef J, et al:
Hexokinase 2 is a key mediator of aerobic glycolysis and promotes
tumor growth in human glioblastoma multiforme. J Exp Med.
208:313–326. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mueckler M, Caruso C, Baldwin SA, et al:
Sequence and structure of a human glucose transporter. Science.
229:941–945. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu H, Hu YP, Savaraj N, Priebe W and
Lampidis TJ: Hypersensitization of tumor cells to glycolytic
inhibitors. Biochemistry. 40:5542–5547. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chun YS, Yeo EJ, Choi E, et al: Inhibitory
effect of YC-1 on the hypoxic induction of erythropoietin and
vascular endothelial growth factor in Hep3B cells. Biochem
Pharmacol. 61:947–954. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhu J, Cui G, Chen M, et al: Expression of
R132H mutational IDH1 in human U87 glioblastoma cells affects the
SREBP1a pathway and induces cellular proliferation. J Mol Neurosci.
50:165–171. 2013. View Article : Google Scholar
|
|
23
|
Bralten LB, Kloosterhof NK, Balvers R, et
al: IDH1 R132H decreases proliferation of glioma cell lines in
vitro and in vivo. Ann Neurol. 69:455–463. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Griguer CE, Oliva CR and Gillespie GY:
Glucose metabolism heterogeneity in human and mouse malignant
glioma cell lines. J Neurooncol. 74:123–133. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lunt SY and Vander Heiden MG: Aerobic
glycolysis: meeting the metabolic requirements of cell
proliferation. Annu Rev Cell Dev Biol. 27:441–464. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vander Heiden MG, Cantley LC and Thompson
CB: Understanding the Warburg effect: the metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Marin-Hernandez A, Gallardo-Perez JC,
Ralph SJ, Rodriguez-Enriquez S and Moreno-Sanchez R: HIF-1alpha
modulates energy metabolism in cancer cells by inducing
over-expression of specific glycolytic isoforms. Mini Rev Med Chem.
9:1084–1101. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Finley LW, Carracedo A, Lee J, et al:
SIRT3 opposes reprogramming of cancer cell metabolism through
HIF1alpha destabilization. Cancer Cell. 19:416–428. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dang CV, Le A and Gao P: MYC-induced
cancer cell energy metabolism and therapeutic opportunities. Clin
Cancer Res. 15:6479–6483. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mathupala SP, Rempel A and Pedersen PL:
Glucose catabolism in cancer cells: identification and
characterization of a marked activation response of the type II
hexokinase gene to hypoxic conditions. J Biol Chem.
276:43407–43412. 2001. View Article : Google Scholar : PubMed/NCBI
|
